Please enable JavaScript to continue using this application.

Compare $DMRA vs $TSHA | Chartloom

Compare

$DMRA vs $TSHA

Damora Therapeutics Inc · Taysha Gene Therapies Inc

DMRA

Damora Therapeutics Inc

TSHA

Taysha Gene Therapies Inc

Compare $DMRA vs $TSHA

Comparing Damora Therapeutics Inc and Taysha Gene Therapies Inc

DMRADamora Therapeutics Inc

TSHATaysha Gene Therapies Inc

DMRADamora Therapeutics Inc

Market cap

$1.30B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-17.4%

52W performance

-17.4%

FCF yield

-3.4%

TSHATaysha Gene Therapies Inc

Market cap

$1.44B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

664.56x

Rev growth (TTM)

-32.3%

YTD performance

-14.5%

52W performance

-11.3%

FCF yield

-9.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

DMRA

TSHA

Detailed metrics comparison

DMRA

Damora Therapeutics Inc

TSHA

Taysha Gene Therapies Inc

Market Cap

DMRA$1.30B

TSHA$1.44B

Enterprise Value

DMRA$757M

TSHA$1.03B

Price

DMRA$21.08

TSHA$4.49

P/E Ratio

DMRAN/A

TSHAN/A

P/S Ratio

DMRA0.00x

TSHA261.77x

EV/Sales

DMRA0.00x

TSHA187.75x

EV/EBITDA

DMRA0.00x

TSHA0.00x

P/B Ratio

DMRA2.47x

TSHA3.90x

P/FCF Ratio

DMRAN/A

TSHAN/A

EV/FCF

DMRA-17.00x

TSHA-7.77x

PEG Ratio

DMRAN/A

TSHAN/A

Forward P/E (NTM)

DMRAN/A

TSHAN/A

Forward P/S (NTM)

DMRAN/A

TSHA664.56x

Revenue (TTM)

DMRA$0

TSHA$5M

Revenue Growth (YoY)

DMRAN/A

TSHA-32.3%

Forward Rev Growth

DMRA346.9%

TSHA1272.3%

Gross Margin (TTM)

DMRA0.0%

TSHA0.0%

Operating Margin (TTM)

DMRA0.0%

TSHA0.0%

EBITDA Margin (TTM)

DMRA0.0%

TSHA-2833.6%

Net Margin (TTM)

DMRA0.0%

TSHA-2728.0%

FCF Margin (TTM)

DMRAN/A

TSHA-2417.0%

Net Income (TTM)

DMRA$-265M

TSHA$-150M

FCF (TTM)

DMRA$-45M

TSHA$-133M

EPS (TTM)

DMRA-$4.34

TSHA-$0.41

ROE (TTM)

DMRA-8306.0%

TSHA-5619.0%

ROA (TTM)

DMRA-7849.0%

TSHA-4184.0%

ROIC (TTM)

DMRA-8306.0%

TSHA-4729.0%

Cash

DMRA$541M

TSHA$455M

Debt

DMRA$0

TSHA$49M

Net Cash/Debt

DMRA$541M

TSHA$406M

Current Ratio (TTM)

DMRA19.73x

TSHA17.76x

Quick Ratio (TTM)

DMRA19.70x

TSHA17.57x

Debt/Equity (TTM)

DMRA0.00x

TSHA0.13x

Debt/Assets (TTM)

DMRA0.0%

TSHA0.0%

Interest Coverage (TTM)

DMRAN/A

TSHAN/A

Net Debt/EBITDA (TTM)

DMRA0.00x

TSHA0.00x

Beta

DMRA-4.05

TSHA1.37

52W Performance

DMRA-17.4%

TSHA-11.3%

YTD Performance

DMRA-17.4%

TSHA-14.5%

% from 52W High

DMRA-39.6%

TSHA-38.5%

% from 52W Low

DMRA27.8%

TSHA21.6%

Asset Turnover (TTM)

DMRA0.00x

TSHA0.04x

FCF Yield (TTM)

DMRA-3.4%

TSHA-9.2%

Earnings Yield (TTM)

DMRA-20.4%

TSHA-10.4%

Dividend Yield (TTM)

DMRAN/A

TSHAN/A

Rule of 40

DMRA0.0

TSHA-2,449.3

EV/GP/RG

DMRAN/A

TSHAN/A

Ticker research

View DMRA research View TSHA research

Metric	DMRA Damora Therapeutics Inc	TSHA Taysha Gene Therapies Inc
Market & Valuation
Market Cap	$1.30B	$1.44B
Enterprise Value	$757M	$1.03B
Price	$21.08	$4.49
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	261.77x
EV/Sales	0.00x	187.75x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.47x	3.90x
P/FCF Ratio	N/A	N/A
EV/FCF	-17.00x	-7.77x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	664.56x
Revenue & Growth
Revenue (TTM)	$0	$5M
Revenue Growth (YoY)	N/A	-32.3%
Forward Rev Growth	346.9%	1272.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-2833.6%
Net Margin (TTM)	0.0%	-2728.0%
FCF Margin (TTM)	N/A	-2417.0%
Net Income (TTM)	$-265M	$-150M
FCF (TTM)	$-45M	$-133M
EPS (TTM)	-$4.34	-$0.41
ROE (TTM)	-8306.0%	-5619.0%
ROA (TTM)	-7849.0%	-4184.0%
ROIC (TTM)	-8306.0%	-4729.0%
Financial Health
Cash	$541M	$455M
Debt	$0	$49M
Net Cash/Debt	$541M	$406M
Current Ratio (TTM)	19.73x	17.76x
Quick Ratio (TTM)	19.70x	17.57x
Debt/Equity (TTM)	0.00x	0.13x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-4.05	1.37
52W Performance	-17.4%	-11.3%
YTD Performance	-17.4%	-14.5%
% from 52W High	-39.6%	-38.5%
% from 52W Low	27.8%	21.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.04x
FCF Yield (TTM)	-3.4%	-9.2%
Earnings Yield (TTM)	-20.4%	-10.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-2,449.3
EV/GP/RG	N/A	N/A
Ticker research	View DMRA research	View TSHA research

Valuation

P/S Ratio

DMRA

0.00x

TSHA

261.77x

EV/FCF

DMRA

-17.00x

TSHA

-7.77x

Growth & revenue

Revenue Growth TTM

TSHA

-32.3%

Forward Revenue Growth

TSHA

1272.3%

DMRA

346.9%

Profitability & performance

Gross Margin

DMRA

0.0%

TSHA

0.0%

ROE

TSHA

-5619.0%

DMRA

-8306.0%

FCF Yield %

DMRA

-3.4%

TSHA

-9.2%

52-Week Performance

TSHA

-11.3%

DMRA

-17.4%

Detailed metrics comparison

DMRA

Damora Therapeutics Inc

TSHA

Taysha Gene Therapies Inc

Market Cap

DMRA$1.30B

TSHA$1.44B

Enterprise Value

DMRA$757M

TSHA$1.03B

Price

DMRA$21.08

TSHA$4.49

P/E Ratio

DMRAN/A

TSHAN/A

P/S Ratio

DMRA0.00x

TSHA261.77x

EV/Sales

DMRA0.00x

TSHA187.75x

EV/EBITDA

DMRA0.00x

TSHA0.00x

P/B Ratio

DMRA2.47x

TSHA3.90x

P/FCF Ratio

DMRAN/A

TSHAN/A

EV/FCF

DMRA-17.00x

TSHA-7.77x

PEG Ratio

DMRAN/A

TSHAN/A

Forward P/E (NTM)

DMRAN/A

TSHAN/A

Forward P/S (NTM)

DMRAN/A

TSHA664.56x

Revenue (TTM)

DMRA$0

TSHA$5M

Revenue Growth (YoY)

DMRAN/A

TSHA-32.3%

Forward Rev Growth

DMRA346.9%

TSHA1272.3%

Gross Margin (TTM)

DMRA0.0%

TSHA0.0%

Operating Margin (TTM)

DMRA0.0%

TSHA0.0%

EBITDA Margin (TTM)

DMRA0.0%

TSHA-2833.6%

Net Margin (TTM)

DMRA0.0%

TSHA-2728.0%

FCF Margin (TTM)

DMRAN/A

TSHA-2417.0%

Net Income (TTM)

DMRA$-265M

TSHA$-150M

FCF (TTM)

DMRA$-45M

TSHA$-133M

EPS (TTM)

DMRA-$4.34

TSHA-$0.41

ROE (TTM)

DMRA-8306.0%

TSHA-5619.0%

ROA (TTM)

DMRA-7849.0%

TSHA-4184.0%

ROIC (TTM)

DMRA-8306.0%

TSHA-4729.0%

Cash

DMRA$541M

TSHA$455M

Debt

DMRA$0

TSHA$49M

Net Cash/Debt

DMRA$541M

TSHA$406M

Current Ratio (TTM)

DMRA19.73x

TSHA17.76x

Quick Ratio (TTM)

DMRA19.70x

TSHA17.57x

Debt/Equity (TTM)

DMRA0.00x

TSHA0.13x

Debt/Assets (TTM)

DMRA0.0%

TSHA0.0%

Interest Coverage (TTM)

DMRAN/A

TSHAN/A

Net Debt/EBITDA (TTM)

DMRA0.00x

TSHA0.00x

Beta

DMRA-4.05

TSHA1.37

52W Performance

DMRA-17.4%

TSHA-11.3%

YTD Performance

DMRA-17.4%

TSHA-14.5%

% from 52W High

DMRA-39.6%

TSHA-38.5%

% from 52W Low

DMRA27.8%

TSHA21.6%

Asset Turnover (TTM)

DMRA0.00x

TSHA0.04x

FCF Yield (TTM)

DMRA-3.4%

TSHA-9.2%

Earnings Yield (TTM)

DMRA-20.4%

TSHA-10.4%

Dividend Yield (TTM)

DMRAN/A

TSHAN/A

Rule of 40

DMRA0.0

TSHA-2,449.3

EV/GP/RG

DMRAN/A

TSHAN/A

Ticker research

View DMRA research View TSHA research

Metric	DMRA Damora Therapeutics Inc	TSHA Taysha Gene Therapies Inc
Market & Valuation
Market Cap	$1.30B	$1.44B
Enterprise Value	$757M	$1.03B
Price	$21.08	$4.49
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	261.77x
EV/Sales	0.00x	187.75x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.47x	3.90x
P/FCF Ratio	N/A	N/A
EV/FCF	-17.00x	-7.77x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	664.56x
Revenue & Growth
Revenue (TTM)	$0	$5M
Revenue Growth (YoY)	N/A	-32.3%
Forward Rev Growth	346.9%	1272.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-2833.6%
Net Margin (TTM)	0.0%	-2728.0%
FCF Margin (TTM)	N/A	-2417.0%
Net Income (TTM)	$-265M	$-150M
FCF (TTM)	$-45M	$-133M
EPS (TTM)	-$4.34	-$0.41
ROE (TTM)	-8306.0%	-5619.0%
ROA (TTM)	-7849.0%	-4184.0%
ROIC (TTM)	-8306.0%	-4729.0%
Financial Health
Cash	$541M	$455M
Debt	$0	$49M
Net Cash/Debt	$541M	$406M
Current Ratio (TTM)	19.73x	17.76x
Quick Ratio (TTM)	19.70x	17.57x
Debt/Equity (TTM)	0.00x	0.13x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-4.05	1.37
52W Performance	-17.4%	-11.3%
YTD Performance	-17.4%	-14.5%
% from 52W High	-39.6%	-38.5%
% from 52W Low	27.8%	21.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.04x
FCF Yield (TTM)	-3.4%	-9.2%
Earnings Yield (TTM)	-20.4%	-10.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-2,449.3
EV/GP/RG	N/A	N/A
Ticker research	View DMRA research	View TSHA research